Back to search results

Intermittent Fasting for Individuals at High Risk for Pancreatic Cancer

This study is looking at an eating pattern called intermittent fasting (IF) in people who are at high risk for pancreatic cancer. Intermittent fasting means you would fast for 16 hours each day and have an 8-hour window for eating. The main goal is to see if this eating pattern is safe and practical for you to follow. Researchers also want to see if intermittent fasting changes certain biological markers (like those related to metabolism, inflammation, or gut bacteria) or imaging results. This study is open to adults aged 18 and older who have been identified as high risk for pancreatic cancer. The study plans to enroll 20 participants, but its current status is unclear.

Study design
This is an interventional study that plans to enroll 20 participants. It is not specified if it is randomized or blinded.
What's involved
You would follow an intermittent fasting schedule, fasting for 16 consecutive hours each day and eating within an 8-hour window.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07513116

Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening

Not Yet Recruiting
NAAges 18+Interventional
M.D. Anderson Cancer Center
~20 participants
Updated 2026-04-14 on ClinicalTrials.gov
What's tested:intermittent fasting

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs).
Measured over Through study completion; an average of 1 year.

Conditions

Evaluating
Intermittent Fasting
Pancreatic Cancer

Explore related trials

Pancreatic Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Florencia McAllister, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Florencia McAllister, MD
[email protected]
713-745-0914
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
High-risk status may include one or more of the following:
Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk
Family history of pancreatic ductal adenocarcinoma (PDAC)
Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN)
New-onset diabetes mellitus is considered suspicious for pancreatic cancer
History of recurrent or chronic pancreatitis
Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.
Participants are able to understand and are willing to sign a written informed consent document.
Both English-speaking and non-English-speaking participants are eligible for participation
Participants are willing to make a change in eating time patterns.
Participants are willing to provide App-tracked fasting time data over the course of the study.

Exclusion

BMI \< 18.5 Kg/m2
Documented history of symptomatic hypoglycemia
Pregnant or breastfeeding women
Cognitively impaired individuals

What this trial measures

  • Safety and adverse events (AEs).Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0